Type Ib is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multiple systemic burdens. Early identification and normalisation of the disease are essential for improving the prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathology tests.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of type Ib requires individualized management, usually including drug therapy, rehabilitation, regular follow-up, and other multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic disorders have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of diabetes mellitus type Ib. The platform serves a team of domestic and foreign experts in the field of genetic metabolism linked to the Chinese international medical service system, providing the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.